Abstract: The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.
H odgkin lymphoma (HL) accounts for 10% of all lymphomas and 0.6% of all cancers in the developed world. In the United States, it is estimated that 9000 new cases will be diagnosed in 2015, and approximately 1150 will die of their disease. Hodgkin lymphoma is histologically defined by rare mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells residing in a sea of inflammatory cells. Morphologically, it is known by its contiguous spread through the lymph nodes. The HRS cells are derived from germinal center B cells but phenotypically lose the expression of typical B-cell markers.
Despite an excellent cure rate with modern frontline HL therapy, approximately 15% to 20% of patients are not cured with first-line or second-line therapy and will require additional treatments. For those who are cured, treatment-related late toxicities continue to impact patients' quality of life and survival. Therefore, there is need to develop new therapeutic agents to further improve the current cure rate and to reduce treatment toxicity. The HRS cells are characterized by the expression of CD30 receptors. CD30 is a transmembrane glycoprotein that belongs to the tumor necrosis factor receptor superfamily.
1 CD30 expression is very restricted, making it an ideal therapeutic target for monoclonal antibodies.
Brentuximab vedotin is an antibody-drug conjugate (ADC) that was developed by conjugating the tubulin toxin monomethyl auristatin E (MMAE) to the chimeric monoclonal anti-CD30 antibody cAC10. On average, 4 molecules of MMAE are conjugated to 1 cAC10. After binding to CD30, brentuximab vedotin is internalized and processed into lysosomal vesicles, leading to the release of MMAE from the antibody by reduction or acid hydrolysis within the lysosomes. Subsequently, MMAE is released into cytoplasm and inhibits microtubule polymerization, leading to cell cycle arrest followed by cell death (Fig. 1) . As HRS cells die, a small amount of MMAE is released into the tumor microenvironment, which can kill neighboring cells by a CD30-independent manner.
The first-in-man phase I study of brentuximab vedotin was conducted in 45 patients with relapsed or refractory CD30-positive lymphomas. Brentuximab vedotin was administered by short intravenous infusion every 3 weeks. The trial demonstrated the safety of the drug and provided encouraging early efficacy data, as the treatment resulted in tumor reductions in the majority of patients. 2 Subsequently, a pivotal phase II trial was conducted in 102 patients with refractory or relapsed disease after autologous stem cell transplant (ASCT). Remarkably, 75% of patients had a response, with 34% having a complete response (CR). With a long-term follow-up, approximately 25% of the patients remained in remission after 4 years. 3 Treatment with brentuximab vedotin is generally well tolerated. The most common treatment-related adverse effects of any grade were peripheral neuropathy (42%), nausea (35%), and fatigue (34%). In 8% of patients, grade 3 or 4 neuropathy was observed, requiring dose interruption and/or reduction. 3, 4 In rare cases, pancreatitis and progressive multifocal leukoencephalopathy were also reported.
DEVELOPMENT OF BRENTUXIMAB VEDOTIN IN FRONTLINE THERAPY
Given the high response rate, and good safety profile, brentuximab vedotin is now being incorporated with several frontline regimens for the treatment of patients with classic HL. The goals of these treatment programs are to improve the cure rate, reduce the number of treatment cycles, or eliminate the need for consolidation with radiation therapy.
Initially, brentuximab vedotin was combined with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) for the treatment of patients with advanced-stage HL. In this phase I study, brentuximab vedotin was administered every 2 weeks with each cycle of ABVD. In phase II, the recommended dose was 1.2 mg/kg. However, when brentuximab vedotin was combined with full doses of ABVD, 40% of the patients developed interstitial pneumonitis. Subsequently, bleomycin was eliminated from the regimen, and patients were treated with AVD (adriamycin, vinblastine, dacarbazine) plus brentuximab vedotin, with no further lung toxicity being observed. This novel regimen resulted in a 3-year overall survival (OS) of 100%, and a 3-year failure-free survival of 96%. 5, 6 Based on these promising results, a randomized phase III study was initiated comparing standard ABVD with AVD plus brentuximab vedotin in a different strategy, the German Hodgkin Lymphoma Study Group incorporated brentuximab vedotin with a modified version of their BEACOPP regimen to produce the novel regimen of BrECAPP; however, few data are available on the safety and efficacy of this approach. 7 The outcome of standard ABVD therapy in elderly patients with HL remains disappointing, and these patients need more effective but tolerable new treatment strategies. Ongoing clinical trials with BV (brentuximab, vedotin) as a single agent are being explored specifically in the population of 60 years or older, with preliminary data showing an overall response rate (ORR) of greater than 90% and complete remission seen in 70%, with a median progression-free survival (PFS) of 8.7 months. 8 Also tested in this age group was the combination of BV with dacarbazine.
Although the power of the study is small, it showed ORR of 100%, with CR being 33% and partial response being 66% 9 (Table 1) . Brentuximab vedotin is also incorporated in the management of patients with early-stage HL, with encouraging results. In 1 study, patients were initially treated with single-agent brentuximab vedotin for 2 cycles, followed by 4 to 6 cycles of AVD plus brentuximab vedotin. With a relatively short-term follow-up, the 14-month PFS was 90%, and the OS was 97%. 10 In a different strategy, patients with unfavorable early-stage HL were treated with brentuximab vedotin + AVD for 4 cycles followed by involved-field radiation therapy (IFRT). Thus far, of 19 earlystage patients with unfavorable prognosis, over 90% achieved positron emission topography (PET) negativity with a Deauville score of <4 after 2 or 4 cycles. No patients had pulmonary toxicity, making this regimen safe and effective. 11 
PRETRANSPLANT SALVAGE THERAPY
Approximately 20% to 30% of HL patients have refractory or relapsed disease after frontline therapy. Patients typically undergo salvage chemotherapy followed by ASCT. While many platinum-based and gemcitabine-based salvage regimens produce high response rates, exceeding 60% to 70%, the complete remission rates achieved with these regimens remain rather low. To FIGURE 1. Brentuximab vedotin mechanism of action. As an antibody for CD30, BV then enters cell via endocytosis. In the lysosome, the cytotoxin MMAE gets released. When MMAE enters the nucleus, it disrupts mitosis at the microtubulin level, causing apoptosis. 18 Adults aged >60 y ORR= 92%, CR = 73%, PFS = 10.5 mo 27 BV +dacarbazine 9 Adults aged >60 y ORR = 100%, CR 33%, PR = 66% 6 improve the CR rate of salvage regimens, brentuximab vedotin was combined with ifosfamide, carboplatin, and etoposide (ICE). 12 In this phase II trial, brentuximab vedotin was given as a single agent for 2 cycles, with each cycle being 3 weekly doses of brentuximab vedotin followed by 1 week of rest. Patients who achieved PET-negative response were allowed to proceed directly to stem cell collection followed by ASCT. Otherwise, patients were treated with augmented doses of ICE followed by ASCT. Using this strategy, 26% (12/46) of patients achieved PET-negative disease after 2 cycles of brentuximab vedotin. The 2-year OS and eventfree survival were 95% and 80%, respectively. In a separate phase I/II study, brentuximab vedotin was combined with bendamustine in 45 patients with first relapse. Patients received up to 6 cycles of the combination, followed by ASCT, then maintenance with brentuximab vedotin for up to 16 doses. Eighty-two percent of patients achieved CR before ASCT, with 94% ORR. 13 Brentuximab vedotin was also combined with gemcitabine, vinorelbine, and doxorubicin on day 1 followed by brentuximab vedotin on day 8 every 3 weeks as a bridge to transplant. The ORR was 100%, with 8 of 11 patients achieving CR 14 ( Fig. 2) .
BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER ASCT
Patients with relapsed and refractory HL are typically treated with second-line salvage therapy followed by ASCT. At best, this approach can cure approximately 60% of transplant-eligible patients. To improve on the outcome of ASCT, 2 strategies have been explored. In the first one, as discussed earlier, brentuximab vedotin is combined with pretransplant salvage regimens to improve the CR rate. In the second, brentuximab vedotin is administered after ASCT as a consolidation, to prevent relapsed disease. To test the second approach, a phase III, randomized, double-blind, placebo-controlled trial compared brentuximab vedotin consolidation with placebo in patients with high-risk disease (AETHERA trial). 15 Patients were treated with either brentuximab vedotin for 16 doses or placebo, starting 30 to 45 days after ASCT. The 2-year PFS for patients receiving brentuximab vedotin or placebo were 65% and 45%, respectively. However, there was no difference in the OS, as 85% of patients in the placebo group received brentuximab vedotin after progression. 15 Based on these data, brentuximab vedotin was approved by the Food and Drug Administration for consolidation therapy after ASCT.
FUTURE DIRECTIONS
As discussed earlier, brentuximab vedotin produces 75% response rate in patients with relapsed HL after receiving ASCT. However, despite this high response rate, the majority of responses are partial and short lived. To improve the CR rate and response duration, it will be important to combine brentuximab vedotin with other active agents. Ongoing combinations include the histone deacetylase inhibitor mocetinostat (NCT02429375) and the mTOR inhibitor everolimus (NCT02254239, NCT01022996). With the recent reports of significant clinical activity of immune checkpoint inhibitors targeting PD1, future combination of brentuximab vedotin plus PD1-or PDL1-blocking antibodies is warranted. Should these combinations prove to be safe and highly active, this doublet can be incorporated with other active agents and tested in patients with newly diagnosed disease with highrisk features (Table 2 ). 
